Navigation Links
Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2010 Financial Results
Date:10/26/2010

THE WOODLANDS, Texas, Oct. 26 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that it will release its third quarter 2010 financial results on Friday, November 5, 2010 before the financial markets open.  Lexicon management will hold a conference call to discuss its clinical development progress and financial results for the quarter at 11:00 a.m. Eastern Time that same day.

The dial-in number for the conference call is 888-220-1244 (within the US/Canada) or 706-679-5615 (international).  The conference ID for all callers is 20791091.  Investors can access a live webcast of the call at www.lexpharma.com.  An archived version of the webcast will be available on the website through November 12, 2010.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2009, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Pharmaceuticals to Present at BioCentury Newsmakers in the Biotech Industry Conference Oct. 22nd
2. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2010 Financial Results
3. Lexicon Pharmaceuticals Announces Reacquisition of All Rights to Symphony Icon Programs
4. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
5. Lexicon Presents Positive Outcome in IBS Patients Treated With LX1031 and Data Supporting Mechanism of Action
6. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2010 Financial Results
7. Lexicon to Present at BIO International Convention
8. Lexicon to Present Phase 2 Clinical Data for IBS Drug Candidate at Digestive Disease Week
9. Lexicon Announces Proposed $95 Million Common Stock Offering
10. Lexicon to Report Fourth Quarter and Year End 2009 Financial Results on February 23, 2010
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... July 21, 2017 Did you know that PhRMA member ... Or that combined spending on brand medicines, generics and the supply ... brands accounting for just half of this (7 percent)? Or that ... of the world,s venture capital investments in high-growth biopharmaceutical startups? ... ...
(Date:7/19/2017)... July 19, 2017  Mako Medical Laboratories partnered with ... Military Family Assistance Fund (MFA) to bring 140 soldiers ... visit with their families one last time before being ... the travel and logistics needed for these soldiers. "Mako ... and their families. We just wish we could bring ...
(Date:7/15/2017)... July 15, 2017 Enterin Inc., a ... Parkinson,s disease (PD), today announced the completion of a $12.7 ... New Ventures III, as well as the participation of existing ... thrilled to have the support of New Ventures III and ... as validation of the potential of our platform technology to ...
Breaking Medicine Technology:
(Date:7/24/2017)... CLARA, CA (PRWEB) , ... July 24, 2017 , ... ... and financial organizations, today announced it has partnered with WALLIX to expand ... Special Publication 800-171 . , There are a number of ways to address the ...
(Date:7/24/2017)... ... July 24, 2017 , ... Anyone who uses scales know they have ... a pharmacist using that same scale to dispense medication. The first example is an ... illustrations show why it is important to have the right balance for the process. ...
(Date:7/24/2017)... BEACH, Calif. (PRWEB) , ... July 24, 2017 , ... ... ranging from food addiction to sexual abuse, and how she has overcome them. “Forbidden ... traumatic instances in her life and how she has risen above. , In “Memories,” ...
(Date:7/24/2017)... Church, VA (PRWEB) , ... July 24, 2017 ... ... figuring out how to change manufacturers future. , The agency is hammering out ... Cures Act, one of the farthest-ranging laws ever to affect FDA-regulated firms. The ...
(Date:7/24/2017)... ... ... Short Walk to the Mailbox”: a remarkable memoir of an unconventional courtship. “A ... Ed Clark is a church music director and choral conductor. He has served ... leader for over fifty years. He has a master’s degree in church music ...
Breaking Medicine News(10 mins):